Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (LB-04-THAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01642758
Recruitment Status : Completed
First Posted : July 17, 2012
Last Update Posted : March 14, 2013
Sponsor:
Collaborator:
HemaQuest Pharmaceuticals Inc.
Information provided by (Responsible Party):
Boston University

Tracking Information
First Submitted Date  ICMJE July 12, 2012
First Posted Date  ICMJE July 17, 2012
Last Update Posted Date March 14, 2013
Study Start Date  ICMJE May 2012
Actual Primary Completion Date November 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 24, 2012)
To measure changes from baseline in total hemoglobin when HQK-1001 is administered orally for 26 weeks in subjects with beta thalassemia intermedia. [ Time Frame: 6 months ]
Baseline hemoglobin levels will be determined in each subject and averaged from levels obtained on a screening visit and on day one of the study, before any drug is taken. Hemoglobin levels will then be analyzed every 4 weeks during 26 weeks of taking the study drug and for 4 weeks after the dosing is completed. Changes from baseline will be determined.
Original Primary Outcome Measures  ICMJE
 (submitted: July 16, 2012)
To evaluate the effect of HQK-1001 on total hemoglobin when administered orally for 26 weeks in subjects with beta thalassemia intermedia. [ Time Frame: 6 months ]
Baseline hemoglobin levels will be determined in each subject and averaged from levels obtained on a screening visit and on day one of the study, before any drug is taken. Hemoglobin levels will then be analyzed every 4 weeks during 26 weeks of taking the study drug and for 4 weeks after the dosing is completed. Changes from baseline will be determined.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2012)
  • To measure the number of adverse events which occur with HQK-1001 treatment when given over 26 weeks in beta thalassemia intermedia. [ Time Frame: 6 months ]
    Adverse events which occur during HQK-1001 administration for 26 weeks will be recorded every 4 weeks.
  • To measure changes from baseline in HbF during treatment with HQK-1001 for 26 weeks in beta thalassemia intermedia. [ Time Frame: 6 months ]
    Levels of HbF will be averaged from a screening visit and day 1 of the study, prior to any drug treatment. HbF levels will then be measured every 4 weeks during treatment and for 4 weeks after the treatment, and compared to each subject's baseline value. The number of subjects in which an increase in HbF develops above individuals' average baseline value will be obtained.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 16, 2012)
  • To determine the number of adverse events which occur with HQK-1001 treatment when given over 26 weeks in beta thalassemia intermedia. [ Time Frame: 6 months ]
    Adverse events which occur during HQK-1001 administration for 26 weeks will be determined every 4 weeks.
  • To determine changes from baseline in HbF with treatment with HQK-1001 for 26 weeks in beta thalassemia intermedia. [ Time Frame: 6 months ]
    Levels of HbF will be averaged from a screening visit and day 1 of the study, prior to any drug treatment. HbF levels will then be measured every 4 weeks during treatment and for 4 weeks after the treatment, and compared to each subject's baseline value. The number of subjects in which an increase in HbF develops above baseline will be determined.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon
Official Title  ICMJE An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia
Brief Summary

Beta thalassemia intermedia syndromes are genetic anemias caused by mutations which reduce production of beta globin, a major component of adult hemoglobin A, the protein which delivers oxygen throughout the body. Patients suffer from poor growth, fatigue, heart failure, endocrine deficiencies, and eventually, many require chronic blood transfusions. There is no approved therapeutic for the deficiency of beta globin chains in beta thalassemia.

This trial will study an oral therapeutic which stimulates production of fetal globin, an alternate type which is produced by all humans, but is normally switched off in infancy. This type of globin can compensate for the missing protein in beta thalassemia.

Detailed Description

This is a trial of an experimental oral medicine which stimulates production of fetal hemoglobin, an innate type of hemoglobin which is normally made but is suppressed in infancy. Fetal globin (HbF) can perform the function of the missing beta globin and reduce anemia in beta thalassemia, when it is produced in higher amounts than normal.

In this trial, 10 patients with beta thalassemia intermedia in Lebanon will all receive the study drug for 6 months at a dose which has been previously shown to be safe in normal volunteers and in beta thalassemia and sickle cell patients and to stimulate fetal globin production in many, when given for brief periods. The purpose of this trial is the following:

  1. To determine if total hemoglobin levels increase above baseline in some subjects when the study drug is taken for 26 weeks.
  2. To determine if fetal globin is increased above baseline levels in a proportion of subjects when the study drug is taken for 26 weeks.
  3. To determine the number of adverse events which occur with 26 weeks of administration of the study drug in beta thalassemia intermedia subjects.

After a screening period, the subjects will take the study drug at home once a day. They will be seen once every 4 weeks for examinations and laboratory tests during the dosing period and for 4 weeks afterwards.

This trial will provide an important step in evaluating a potential treatment for patients with beta thalassemia intermedia, that can be used around the world, if it is effective and safe.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Beta Thalassemia Intermedia
Intervention  ICMJE Drug: Sodium 2,2 dimethylbutyrate
Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
Other Name: ST20
Study Arms  ICMJE Experimental: Sodium 2,2 dimethylbutyrate
A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
Intervention: Drug: Sodium 2,2 dimethylbutyrate
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 16, 2012)
10
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 2013
Actual Primary Completion Date November 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of beta thalassemia intermedia
  • Ages 16-50 years
  • Average total Hgb levels between 6.0 and 9.0 gm/dl within 30 days of initial dose of study drug
  • Able to comply with all study procedures
  • If female and of childbearing potential, must have a documented negative pregnancy test prior to entry and every 4 weeks

Exclusion Criteria:

  • Red blood cell transfusions within 3 months prior to administration of study drug
  • QT Segment corrected (QTc)> 450 msec
  • Use of Erythropoiesis Stimulating Agents(ESAs)within 9 days of first dose
  • Hydroxyurea treatment within 6 months of first study drug
  • History of significant arrythmias, syncope, or resuscitation
  • Alanine Transaminase (ALT)> 4x upper limit of normal
  • Serum creatinine > 1.5 mg/dl
  • Sse of iron chelating agents within 7 days of first dose
  • Pulmonary hypertension requiring oxygen therapy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years to 50 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Lebanon
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01642758
Other Study ID Numbers  ICMJE HQK-P2-THAL
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boston University
Study Sponsor  ICMJE Boston University
Collaborators  ICMJE HemaQuest Pharmaceuticals Inc.
Investigators  ICMJE
Study Director: Susan P Perrine, MD Boston University
Principal Investigator: Adlette Inati, MD Chronic Care Center and Rafik Hariri University Hospital, Beirut, Lebanon
PRS Account Boston University
Verification Date March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP